A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT03843125
- Phase
- PHASE3
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Baricitinib — DRUGAdministered orally.
- Placebo — DRUGAdministered orally.
Study Details
The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).
Key Dates
- Start date
- Sep 9, 2019
- Status verified
- May 2023
- Primary completion
- Apr 1, 2022
- Completion
- Apr 1, 2022
Study Design
- Enrollment
- 1,147 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 2 mg BaricitinibParticipants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).
- Experimental: 4 mg BaricitinibParticipants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.
- Experimental: Placebo to 2 mg BaricitinibParticipants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.
- Experimental: Placebo to 4 mg BaricitinibParticipants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.
Primary Outcome Measure
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Week 134 ]
Locations (61)
Find similar trials in Birmingham, AL
By condition
By specialty
By research site
Achieve Clinical Research, LLC· Birmingham, ALArizona Arthritis & Rheumatology Research· Phoenix, AZArizona Arthritis & Rheumatology Associates, P. C.· Tucson, AZWallace Rheumatic Studies Center· Beverly Hills, CAMedvin Clinical Research - Weidmann· Covina, CAProvidence Medical Foundation· Fullerton, CA
Related Studies
- Study of Systemic Lupus ErythematosusRecruiting · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Bethesda, Maryland
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)Recruiting · Hospital for Special Surgery, New York · Chicago, Illinois
- Duke Lupus RegistryRecruiting · Duke University · Durham, North Carolina
- Systemic Lupus Erythematosus in Gullah HealthRecruiting · Medical University of South Carolina · Charleston, South Carolina